Key result
Primary cardiac lymphoma accounts for about 1% of primary cardiac tumors, with combination chemotherapy and radiation therapy considered the treatment of choice to prolong survival up to 5 years.
Population
Patients with primary cardiac lymphoma
Design
Review
Authors
Loading...
Alerts clinicians to rare cardiac masses; leaves open prospective validation of chemoradiation regimens.
Primary cardiac lymphoma is a rare malignancy where combination chemotherapy and radiation therapy is considered the treatment of choice, potentially prolonging survival up to 5 years.
Gowda et al. (2003) conducted a review in Primary cardiac lymphoma. Primary cardiac lymphoma accounts for about 1% of primary cardiac tumors, with combination chemotherapy and radiation therapy considered the treatment of choice to prolong survival up to 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: